Pfizer/Hospira Epogen Biosimilar Rejected; Relief For Amgen
This article was originally published in Scrip
Executive Summary
Pfizer Inc. sneaked the news into its quarterly earnings call on Oct. 27 that its newly acquired subsidiary Hospira Inc. had received a complete response letter earlier this month from the FDA for its epoetin alfa biosimilar – a product Amgen Inc. has been working desperately through the US court system to keep off the market for a little while longer.
You may also be interested in...
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.